drugset / Trial / NCT02208063
A Phase 3 Telavancin Staphylococcus Aureus (S. Aureus) Bacteremia Trial
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a multicenter, randomized, open-label, noninferiority trial of telavancin versus standard IV therapy control (e.g., vancomycin, daptomycin, anti-staphylococcal penicillin (PCN), or cefazolin) in the treatment of subjects with complicated Staphylococcus aureus (S. aureus) bacteremia and SA right-sided infective endocarditis (SA-RIE).
Timeline
- Start
- 2014-12
- Primary completion
- 2018-04-12
- Completion
- 2018-04-12
Outcome
Outcome not reported
Stopped: “Halted due to lack of statistical power. No safety concerns identified.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Cefazolin | Small molecule | — | Intravenous |
| Comparator | Daptomycin | Other / unclassified | — | Intravenous |
| Subject | Telavancin | Other / unclassified | 7.5 mg/kg | Intravenous |
| Comparator | Vancomycin | Other / unclassified | — | Intravenous |
| Comparator | cloxacillin | Other / unclassified | — | — |
| Comparator | nafcillin | Small molecule | — | — |
| Comparator | oxacillin | Small molecule | — | — |